The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Hemophilia treatment is gradually consuming more U.S. payer budget dollars. The increasing cost of factor concentrate and the growing preference for prophylaxis treatment are key factors driving…
MARKET OUTLOOKHospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most common and serious infections in the hospital setting. HABP/VABP…
The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…
No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation…
Market OutlookTargeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule PARP…
Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and…
Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the…